TVM Capital and Chongqing Pharma Form China In-Licensing Fund

TVM Capital Life Science of Germany closed the first tranche of its China BioPharma Capital I fund at $50 Million, with Chongqing Lummy Pharma the strategic partner and apparently the only investor. The Capital I fund will seek to in-license China rights to innovative drugs and medical devices from Western companies, which Lummy will bring to China's market. TVM Capital Life Science describes itself as a group of independent investment advisors and fund managers with offices in Munich, Montreal and, now with the new emphasis, Hong Kong. More details.... Stock Symbol: (SHZ: 300006) Share this with colleagues: // //